Hanmi Pharmaceutical will receive back the rights of "Belbarafenib (HM95573), a target anticancer dr..
Publisher
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the attributed publisher through Google News.
Open via Google NewsAt a glance
- Publisher
- 매일경제
- Region
- Global
- Scope
- discovery
- Published
- September 29, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
This record currently routes through Google News. Confirm important claims against the publisher or a primary record.
Source: 매일경제
Scope: discovery
Evidence: Tier 3 · Aggregated media
Related coverage
More related coverage
Weekly all-cause mortality surveillance: week ending 11 April 2027 (week 16)
How the actual number of deaths in England compare with expected numbers for each week.
Weekly all-cause mortality surveillance: week ending 4 April 2027 (week 15)
How the actual number of deaths in England compare with expected numbers for each week.
Adult social care client level data, England: quarterly update
Official statistics in development on insights from client level data from local authorities, includ...
Adult social care client level data, England: quarterly update to March 2026
Official statistics in development on insights from client level data from local authorities, includ...